Emerging information on the use of rituximab in chronic lymphocytic leukemia

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 2, 2002, Pages 70-74

  Keating, Michael J ^a   O'Brien, Susan ^a   Albitar, Maher ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD5 ANTIGEN; CD59 ANTIGEN; CYCLOPHOSPHAMIDE; DECAY ACCELERATING FACTOR; DIPHENHYDRAMINE; FLUDARABINE; MEMBRANE COFACTOR PROTEIN; PARACETAMOL; RITUXIMAB;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEVER; HUMAN; HYPOTENSION; MALAISE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0036182539     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.30142     Document Type: Conference Paper

References (15)

1. CD20 workshop panel report
2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
3. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
4. Rituximab dose-escalation trial in chronic lymphocytic leukemia
5. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
6. Clinical relevance of circulating CD20 (cCD20) in patients with chronic lymphocytic leukemia (CLL)
7. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
8. Fludarabine synergizes with anti CD20 monoclonal antibody rituximab in complement mediated cell lysis
9. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
10. Combination chemo-antibody therapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL)
11. Combination fludarabine, cyclophosphamide, and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL)
12. Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia: Preliminary results from CALGB 9712
13. Mechanism-based rationales for combination therapies of lymphoid malignancies
14. Quantitative difference in CD20 expression in chronic B-cell lymphocytic leukemia and lymphomas by site and type of disease
15. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia